

### Infusion Therapy - IV Remdesivir Referral Form

- Patients will receive treatment in our community nursing clinics, unless under exceptional circumstances.
- We process only completed referrals (legible, signed, dated). Fax to 613.745.6984 or 1.855.450.8569.

Name		DOB		HCN / VC		
Address				Unit		
City				Postal Code		
Phone		Alt Phone				
<b>Preferred language for service:</b> EN <input type="checkbox"/> FR <input type="checkbox"/> Other <input type="checkbox"/> (specify)						
Diagnosis						
Allergies						
If applicable, Hospital Planned Discharge Date				<b>Infection Control Precautions are DROPLET, AIRBORNE and CONTACT</b>		
<input type="checkbox"/> <b>Use alternate contact (instead of patient) for assessment, due to</b> <input type="checkbox"/> Preference <input type="checkbox"/> Hearing <input type="checkbox"/> Cognition <input type="checkbox"/> Language <input type="checkbox"/> Other (specify)						
Alt Contact Name		Relationship to pt		Phone		
<b>If any answers to the questions below are “No”, we are unable to administer the first dose of IV Remdesivir in the community.</b>					Yes	No
Has the prescriber confirmed the patient does not have any serious allergies / adverse reactions to the ordered medication or related drugs?						
Has the prescriber confirmed the patient does not have anaphylaxis to Remdesivir <b>or</b> anaphylaxis of unknown origin?						
Is the patient at least 18 years old?						
For six hours after receiving the first dose and should an adverse reaction occur, does the patient have access to a working telephone to call 911 or to a hospital within approximately 30 minutes drive from medication administration address?						
To monitor the patient for adverse reactions for six hours after the medication is administered, the patient / SDM understands that a capable adult (18 years or older) should be present in the home or with the patient.						
<b>Treatment</b>	1) <input type="checkbox"/> Patient qualifies for Remdesivir treatment, per Ontario Health and Ministry of Health guidelines as they do not require hospitalization; AND cannot take Paxlovid (nirmatrelvir and ritonavir), e.g., due to a drug interaction or contraindication.					
	2) Date of COVID-19 symptom onset (Day 0 first day of symptoms and Day 1 first full day after the day the symptoms started).			Date of positive test		
	3) <input type="checkbox"/> Remdesivir 200 mg IV on Day 1, 100 mg IV daily on days 2 and 3. All doses via peripheral IV.					
	4) Is this a first dose? <input type="checkbox"/> Yes <input type="checkbox"/> No. <b>If no,</b> Dose 1 date & time _____ Dose 2 date & time _____					
<input type="checkbox"/> I confirmed that the patient does not have any serious allergies or adverse reactions to the ordered or related medications.						
<input type="checkbox"/> I confirmed there are no contraindications to patient receiving IV Remdesivir in the community, including review of recent bloodwork (Cr, ALT, AST & eGFR within three months), hepatic and renal function, pregnancy/breastfeeding status.						
<input type="checkbox"/> I explained the risks of having the first dose in the community to the patient / most responsible person and the patient / most responsible person has given verbal consent.						
<b>Additional Information / Orders</b>						
Physician/NP Name (please print)						
Signature			Date			
If delegate, name of most responsible provider (MRP)			MRP phone number for urgent situations			

Confidential when completed. If you received this form in error, please call us at 1.800.538.0520.